Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285354 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5168130 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4778591 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL741996 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4773208 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535294 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5651326 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL514304 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL581065 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535321 | 1.00 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329730-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | Helsingin Yliopisto (FI) | 2024-03-06 | — | — | EP | disclosed |
| CN-117241784-A | Specific combinations of lipids and methods and uses related thereto | 赫尔辛基大学 | 2023-12-15 | — | — | CN | disclosed |
| WO-2022229441-A2 | A SPECIFIC COMBINATION OF LIPIDS AND METHODS AND USES RELATED THERETO | HELSINGIN YLIOPISTO (FI) | 2022-11-03 | — | — | WO | disclosed |
| US-8936859-B2 | Cyclophosphazene compound, lubricant comprising same, and magnetic disk | MORESCO CORPORATION (JP) | 2015-01-20 | — | — | US | disclosed |
| EP-2565198-B1 | CYCLOPHOSPHAZENE COMPOUND, LUBRICANT COMPRISING SAME, AND MAGNETIC DISK | MORESCO CORP (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-2565198-A1 | CYCLOPHOSPHAZENE COMPOUND, LUBRICANT COMPRISING SAME, AND MAGNETIC DISK | MORESCO Corporation (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130034749-A1 | CYCLOPHOSPHAZENE COMPOUND, LUBRICANT COMPRISING SAME, AND MAGNETIC DISK | MORESCO CORPORATION (JP) | 2013-02-07 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-1991516-A2 | HYDROXYLATED LONG-CHAIN RESVERATROL DERIVATIVES USEFUL AS NEUROTROPHIC AGENTS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007099162-A2 | HYDROXYLATED LONG-CHAIN RESVERATROL DERIVATIVES USEFUL AS NEUROTROPHIC AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-09-07 | — | — | WO | disclosed |
| US-6790971-B1 | AMIDE OR CARBAMATE FUNCTION AT 11 BETA-POSITION; CLAIMED 3-ONE-DIENE INTERMEDIATE HAS HYDROXYMETHYLALKYL GROUP ON 11 POSITION; ANTIPROGESTOMIMETIC; HORMONE-DEPENDENT TUMORS; ANIMAL HUSBANDRY | AVENTIS PHARMA S.A. (FR) | 2004-09-14 | — | — | US | disclosed |
| US-5707982-A | ANTITUMOR | ROUSSEL UCLAF (FR) | 1998-01-13 | — | — | US | disclosed |
| US-5290771-A | 19-nor-steroids | ROUSSEL UCLAF (FR) | 1994-03-01 | — | — | US | disclosed |
| EP-0384842-B1 | 19-Nor steroids substituted at position 11-beta by a hydrocarbon chain containing an amide or carbamate group, their preparation, intermediates, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1993-12-29 | — | — | EP | disclosed |
| US-5149696-A | Antiestrogens | ROUSSEL UCLAF (FR) | 1992-09-22 | — | — | US | disclosed |
| EP-0384842-A1 | 19-Nor steroids substituted at position 11-beta by a hydrocarbon chain containing an amide or carbamate group, their preparation, intermediates, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | DUT 1162/4885 |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | BDNF, NTRK2, NGF | DUT 4678/4885 |
| US-20130034749-A1 | CYCLOPHOSPHAZENE COMPOUND, LUBRICANT COMPRISING SAME, AND MAGNETIC DISK | FXR2, CYFIP2, F2 | DUT 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.